Search Results
Feb 04, 2026, 09:37 ET VPT Expands NewSpace VSC Series with High-Efficiency Point of Load DC-DC Converter
Earth orbits (LEO), and NASA Class D missions where the balance of cost and guaranteed performance is critical. This series is radiation tested to 42 MeV/mg/cm² with no destructive SEE events (SEGR, SEB, SEL) and tested to 40 krad(Si), guaranteed to 30 krad(Si), for TID in accordance with VPT's in–house radiation
More news about: VPT, Inc.
Feb 04, 2026, 09:37 ET VPT Expands NewSpace VSC Series with High-Efficiency Point of Load DC-DC Converter
Earth orbits (LEO), and NASA Class D missions where the balance of cost and guaranteed performance is critical. This series is radiation tested to 42 MeV/mg/cm² with no destructive SEE events (SEGR, SEB, SEL) and tested to 40 krad(Si), guaranteed to 30 krad(Si), for TID in accordance with VPT's in–house radiation
More news about: VPT, Inc.
Feb 04, 2026, 07:00 ET Final APEX Phase 1b Clinical Results for Kodiak's KSI-101 in Macular Edema Secondary to Inflammation to be Presented at Angiogenesis 2026
levels tested were selected to advance into the Phase 3 program. The PEAK and PINNACLE Phase 3 studies are actively enrolling MESI subjects at the 5 mg and 10 mg dose levels versus sham.About Kodiak Sciences Inc.Kodiak Sciences (Nasdaq: KOD) is a precommercial retina focused biotechnology
More news about: Kodiak Sciences Inc.
Feb 04, 2026, 05:02 ET Foresee Pharmaceuticals Receives the Fourth Positive Recommendation from the DSMB to Continue the Casppian Ph3 Study, for Central Precocious Puberty (CPP)
evaluating the efficacy, safety, and pharmacokinetics of leuprolide (FP-001) 42 mg controlled-release in patients with central (Gonadotropin-Dependent) precocious puberty (CPP). Foresee's leuprolide injectable emulsion, 42 mg (marketed under the brand name CAMCEVI®), is currently approved
More news about: Foresee Pharmaceuticals Co., Ltd.
Feb 03, 2026, 16:11 ET Match Group Announces Fourth Quarter and Full-Year Results
Archer®, Upward®, YuzuTM, Salams®, HERTM, and other smaller brands.Match Group Asia ("MG Asia") consists of the world-wide activity of the brands Pairs® and Azar®.Direct Revenue is revenue that is
More news about: Match Group
Feb 03, 2026, 08:54 ET SYNEVIT® Supports Heart Valve Awareness Day with Bioavailable Calcium powder 1200mg
supply also goes toward things like blood clotting and heart rhythm. The medical site adds that adults need at least 1,000 mg of daily calcium intake and that rises to 1,200 mg with age.This is where CALCEED® can give health-conscious individuals an advantage."It all comes down to bioavailability,"
More news about: Synevit
Feb 03, 2026, 08:00 ET AbbVie Submits Regulatory Applications to FDA and EMA for Upadacitinib (RINVOQ®) in Adults and Adolescents With Vitiligo
tablet. Take RINVOQ exactly as your HCP tells you to use it. RINVOQ is available in 15 mg, 30 mg, and 45 mg extended-release tablets. RINVOQ LQ is taken twice a day with or without food. RINVOQ LQ is available in a 1 mg/mL oral solution. RINVOQ LQ is not the same as RINVOQ tablets. Do not switch between
More news about: AbbVie
Feb 02, 2026, 17:15 ET The Doctor and The Athlete: Powerhouse Duo Disrupts Functional Beverage Market with Science-Backed "Happiness"
supports brain energy metabolism, making it an ideal choice for functional beverages targeting cognitive performance.The formulation combines 150mg of natural caffeine and L-theanine for balanced energy, plus B-vitamins and electrolytes, delivering under 5 calories per can with zero sugar.About
More news about: Kyowa Hakko U.S.A
Feb 02, 2026, 08:30 ET Lupin Launches Dasatinib Tablets in the United States
Dasatinib Tablets, 20 mg, 50 mg, 70 mg, 80 mg, 100 mg, and 140 mg are bioequivalent to Sprycel® Tablets, 20 mg, 50 mg, 70 mg, 80 mg, 100 mg, and 140 mg, of Bristol-Myers Squibb Company, and indicated for the treatment of:newly
More news about: Lupin Limited
Feb 02, 2026, 08:30 ET Canyon Partners Real Estate & MG Properties Acquire Multifamily Property in San Diego
www.canyonpartners.com.About MG PropertiesMG Properties is a privately owned, fully integrated real estate company specializing in the investment, redevelopment, and management of multi-family assets. Headquartered in San Diego, California, MG Properties was founded in 1992 by
More news about: Canyon Partners LLC
Feb 02, 2026, 08:00 ET Crystalys Therapeutics Expands Phase 3 RUBY Study With First Patients Dosed at European Sites
tophaceous gout in people with chronic or undertreated disease. Despite available therapies that aim to reduce uric acid levels below the target 6 mg/dL, a major treatment gap remains between first-line xanthine oxidase inhibitors (XOIs) and last-line uricase therapy. Currently, no suitable second-line
More news about: Crystalys Therapeutics
Feb 02, 2026, 08:00 ET Real-world head-to-head analysis shows 51% reduction in risk of death for patients with metastatic castration-sensitive prostate cancer treated with ERLEADA® (apalutamide) versus darolutamide without docetaxel through 24 months
multinational, double-blinded, placebo-controlled TITAN trial, which evaluated mCSPC patients (n=1052) randomized (1:1) receiving either ERLEADA® 240 mg once daily (n=525) or placebo once daily (n=527).4 "Real-world comparisons can provide critical information to support patient care
More news about: Johnson & Johnson
Jan 30, 2026, 13:00 ET /C O R R E C T I O N -- KIC Ventures/
mechanical failure.Key Findings:70% Lower Wear Rate : AxioMed showed a mean wear rate of just 1.7 mg/MC, compared to 5.7 mg/MC for the prodisc L.Structural Integrity : The one-piece viscoelastic polymer core maintained its performance through lateral
More news about: KIC Ventures
Jan 30, 2026, 09:39 ET Lundbeck presents new real-world data highlighting meaningful improvements in patients severely impacted by migraine initiating Vyepti® (eptinezumab), at HCOP Annual Conference
INFUSE study is a 12-month, prospective, observational study in the US, assessing real-world effectiveness of intravenous (IV) eptinezumab (100 mg or 300 mg) in adults with migraine who previously failed at least one preventive anti-CGRP. Data were collected digitally at baseline, Day 7, and Months 3,
More news about: H. Lundbeck A/S
Jan 30, 2026, 09:35 ET Lundbeck presents new real-world data highlighting meaningful improvements in patients severely impacted by migraine initiating Vyepti® (eptinezumab), at HCOP Annual Conference
INFUSE study is a 12-month, prospective, observational study in the US, assessing real-world effectiveness of intravenous (IV) eptinezumab (100 mg or 300 mg) in adults with migraine who previously failed at least one preventive anti-CGRP. Data were collected digitally at baseline, Day 7, and Months 3,
More news about: H. Lundbeck A/S
Jan 30, 2026, 03:47 ET 全球首個偏向型GLP-1埃諾格魯肽注射液獲批
Communications）結果表明：基於療法策略，在經飲食運動干預後血糖控制不佳的成年2型糖尿病患者中，埃諾格魯肽注射液0.6mg、1.2mg單藥治療24周後HbA1c降幅均顯著高於安慰劑組，其中1.2mg組降幅達2.43%。埃諾格魯肽0.6mg、1.2mg組HbA1c<7.0%、HbA1c≤6.5%的達標患者比例顯著高於安慰劑組，其中1.2mg組HbA1c<7.0%的達標比例高達80.3%。結果表明，埃諾格魯肽注射液可以高效降低HbA1c，提高HbA1c達標率，呈現劑量相關性，且療效可穩定持續至52周。EECOH-2研究（已發表於The
More news about: 杭州先為達生物科技股份有限公司
Jan 29, 2026, 09:30 ET MG Properties Acquires Dylan Point Loma Apartments in San Diego
and Brian Cruz with CBRE.ABOUT MG PROPERTIESMG Properties is a privately owned, fully integrated real estate company specializing in the investment, redevelopment, and management of multi-family assets. Headquartered in San Diego, California, MG Properties was founded in 1992 by Mark
More news about: MG Properties
Jan 29, 2026, 09:00 ET USDA Protein Push Signals New Search for Seafood
adults.Potassium: Approximately 300 mg of potassium, supporting the recommended daily intake of 2,600 to 3,400 mg and contributing to heart health by helping regulate blood pressure and reduce stroke risk.Phosphorus: 212 mg of phosphorus, an essential mineral for strong bones
More news about: Wild Alaska Sole Association
Jan 29, 2026, 09:00 ET MAINGEAR Drops Retro98: Looks like it's From 1998, Spec'd for 2026
pre-configured MG-1 systems featuring the newly-released Ryzen 9 9850X3D CPU: MG-1 |
More news about: MAINGEAR
Jan 29, 2026, 07:48 ET A Skyhawk Therapeutics anuncia resultados provisórios de nove meses em pacientes de seu ensaio clínico de fase 1 do SKY-0515 como tratamento para a doença de Huntington
O tratamento com SKY-0515 provoca uma redução dependente da dose da proteína mHTT no sangue de 62% com a dose de 9 mg e uma redução da dose dependente do mRNA PMS1 de 26%. O PMS1 é um fator determinante da expansão da repetição somática CAG e da patologia da DH. O SKY-0515
More news about: Skyhawk Therapeutics
Jan 29, 2026, 07:46 ET Skyhawk Therapeutics anuncia resultados provisionales de nueve meses en pacientes de su ensayo clínico de fase 1 de SKY-0515 como tratamiento para la enfermedad de Huntington
El tratamiento con SKY-0515 da lugar a reducciones dependientes de la dosis de la proteína mHTT en sangre del 62 % con la dosis de 9 mg, y a una reducción dependiente de la dosis del ARNm de PMS1 del 26 %. El PMS1 es un factor clave de la ampliación de la repetición de la citosina-adenina-guanina
More news about: Skyhawk Therapeutics
Jan 28, 2026, 21:21 ET QureBio Ltd. to Present at ASCO 2026 its Q-1802 Phase II Clinical Results
membranous staining), HER2-negative, treatment-naïve, histologically confirmed unresectable locally advanced/metastatic GC/GEJ. Pts received Q-1802 (10 mg/kg or 20 mg/kg Q2W) plus standard XELOX.In this study, no DLT observed; MTD not reached. Most common Q-1802-related ≥3 Grade TEAE: thrombocytopenia
More news about: QureBio Ltd.
Jan 28, 2026, 19:35 ET UT Health San Antonio research shows Alzheimer's prevention potential in pairing cannabis ingredient, anti-inflammatory drug
cardiovascular risk in earlier Alzheimer's trials. For the study, they administered 3 mg/kg of THC and 1 mg/kg of celecoxib per day to mice. This is the human-equivalent in a 165-pound person of 18 mg THC and 6 mg of celecoxib per day.In the new study, the researchers tested low-dose THC alone
More news about: UT Health San Antonio
Jan 28, 2026, 16:15 ET Alliance for Innovation and Infrastructure Appoints Two New Board Members
lies in rigorous analysis, framing policy questions, and helping decision-makers evaluate tradeoffs. We do not engage in partisan disputes. Joyce and MG Shawley bring the judgment and experience needed to ensure Aii continues to engage constructively, credibly, and independently in shaping the national
More news about: Alliance for Innovation and Infrastructure
Jan 28, 2026, 13:20 ET 《自然-通訊》發表埃諾格魯肽注射液Ⅲ期EECOH-1研究結果
EECOH-1研究是一項多中心、隨機、雙盲、安慰劑對照的Ⅲ期臨床研究，在中國32個中心開展，共入組211例經飲食運動干預後血糖控制不佳的成年2型糖尿病（T2DM）患者，按1:1:1比例隨機分配接受每週一次埃諾格魯肽注射液0.6mg、1.2mg或安慰劑雙盲治療24周，完成雙盲治療後，埃諾格魯肽注射液組參與者繼續接受埃諾格魯肽治療，安慰劑組參與者結轉接受埃諾格魯肽治療28周，總治療時長為52周。研究的主要終點為治療24周後經由中心實驗室檢測的糖化血紅蛋白（HbA1c）相對基線的改變。基於療法策略，治療24周後，埃諾格
More news about: Sciwind Biosciences Co., Ltd.